Abstract
Trials of anticoagulants for stroke prevention generally involve patients with frequent and symptomatic atrial fibrillation (AF); however, the growing population of patients with implanted cardiac devices has enabled the detection of subclinical AF. The manufacturer-sponsored ASSERT trial in patients with a dual-chamber pacemaker or implantable cardioverter-defibrillator was designed to evaluate whether a special pacing algorithm would prevent AF and whether …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
